Janssen Pharmaceutica Nv

Rapport Therapeutics, Inc.

Michael K Ameriks

Suchitra Ravula

Brian Ngo Laforteza

Wei Zhang

Gang Chen

Devin M Swanson

Pablo Garcia-Reynaga

Bradley M Savall

Brad M Savall

Dongpei Wu

Cynthia B Berry

Andrew V Samant

Brock T Shireman

Warren Stanfield Wade

Jason Christopher Rech

Terry Patrick Lebold

Chaofeng Huang

Jesus Alcazar

J Guy Breitenbucher

Frank Urban Axe

Kristen L Arienti

Stephen Todd Meyer

Márió Gyuris

Cynthia G B Berry

J A Vega-Ramiro

Brice M Stenne

Jessica L Wall

Jimmy T Liang

Jeannie M Ziff

János Gerencsér

Krisztián Biró

Emma Helen Southgate

Jamie M Schiffer

Miguel Angel Pena Piñon

David Wei Lin

Fabrice Loic Jourdan

Frank U Axe

Miguel Angel Pena PIÑÓN

Cynthia GB Berry

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

Azabenzimidazoles and their use as AMPA receptor modulators

Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R, RR, Rand Rare defined herein.

Monoacylglycerol lipase modulators

Aminocyclobutane compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R, R, R, Rand Rare defined herein.

Aminocyclobutanes as monoacylglycerol lipase modulators

Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R, R, R, R, m, n, o, and p are defined herein.

Azaspirocycles as monoacylglycerol lipase modulators

Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein R, R, R, and R, are defined herein.

Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R, R, R, R, R, R, and Rare defined herein.

Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R,, R, and L are as defined herein.

Cyclobutyl amide monoacylglycerol lipase modulators

Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R, R, R, R, Rand Rare as defined herein.

Aryl piperidines as monoacylglycerol lipase modulators

3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein X, Y, R, R, and Rare defined herein.

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof,  Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

Growing community of inventors

San Diego, CA, United States of America

Michael K Ameriks